Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015486 | 0.88 | HTT (0.71) | HTTFGFR1MAPTKMT2ANPSR1 | |
| SCHEMBL16158486 | 0.82 | FGFR1 (0.59) | HTTFGFR1MAPTKMT2ANPSR1 | |
| SCHEMBL17754446 | 0.81 | MAPT (0.63) | HTTFGFR1MAPTKMT2ANPSR1 | |
| SCHEMBL2642019 | 0.80 | FGFR1 (0.60) | HTTFGFR1 | |
| SCHEMBL27285256 | 0.80 | KDR (0.63) | HTTFGFR1MAPTKMT2ANPSR1 | |
| SCHEMBL2642001 | 0.80 | FGFR1 (0.83) | HTTFGFR1 | |
| SCHEMBL16158540 | 0.80 | FGFR1 (0.83) | HTTFGFR1 | |
| SCHEMBL3417304 | 0.80 | HTT (0.78) | HTTFGFR1POLB | |
| SCHEMBL2641988 | 0.79 | FGFR1 (0.59) | HTTFGFR1MAPTKMT2ANPSR1 | |
| SCHEMBL16148149 | 0.79 | FGFR1 (0.60) | HTTFGFR1MAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200227650-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | DOOSAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
| WO-2019004584-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 두산 | 2019-01-03 | — | — | WO | disclosed |
| WO-2018093107-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | 주식회사 두산 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200227650-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | OR10J3, ORAI2, OR51E2 | HTT 3192/4885FGFR1 4616/4885MAPT 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.